[go: up one dir, main page]

AU7537100A - Assaying in vivo t-cell response upon dna vaccination - Google Patents

Assaying in vivo t-cell response upon dna vaccination

Info

Publication number
AU7537100A
AU7537100A AU75371/00A AU7537100A AU7537100A AU 7537100 A AU7537100 A AU 7537100A AU 75371/00 A AU75371/00 A AU 75371/00A AU 7537100 A AU7537100 A AU 7537100A AU 7537100 A AU7537100 A AU 7537100A
Authority
AU
Australia
Prior art keywords
assaying
vivo
cell response
dna vaccination
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU75371/00A
Inventor
John Tite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU7537100A publication Critical patent/AU7537100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU75371/00A 1999-10-01 2000-09-29 Assaying in vivo t-cell response upon dna vaccination Abandoned AU7537100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9923309 1999-10-01
GBGB9923309.0A GB9923309D0 (en) 1999-10-01 1999-10-01 Assay
PCT/GB2000/003730 WO2001025792A1 (en) 1999-10-01 2000-09-29 Assaying in vivo t-cell response upon dna vaccination

Publications (1)

Publication Number Publication Date
AU7537100A true AU7537100A (en) 2001-05-10

Family

ID=10861991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75371/00A Abandoned AU7537100A (en) 1999-10-01 2000-09-29 Assaying in vivo t-cell response upon dna vaccination

Country Status (5)

Country Link
EP (1) EP1218750A1 (en)
JP (1) JP2003511669A (en)
AU (1) AU7537100A (en)
GB (1) GB9923309D0 (en)
WO (1) WO2001025792A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101882040B1 (en) * 2010-12-21 2018-07-25 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Determination of the efficacy of an anti-mycobacterial vaccination
CN109136282A (en) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 A kind of construction method of HAFFT1 cell

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5507098A (en) * 1995-12-19 1998-03-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhancement of dna immunization through the use of cytokines
WO1999019478A1 (en) * 1997-10-10 1999-04-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (cea)
WO1999065522A1 (en) * 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination

Also Published As

Publication number Publication date
EP1218750A1 (en) 2002-07-03
GB9923309D0 (en) 1999-12-08
WO2001025792A1 (en) 2001-04-12
JP2003511669A (en) 2003-03-25

Similar Documents

Publication Publication Date Title
AU7680300A (en) Human dna sequences
AU5646800A (en) Card-based biosensor device
HUP0201438A3 (en) Dna vaccine - pcv
AU4975300A (en) Dna melting curve analysis
AU5459000A (en) Highly sensitive biological agent probe
AU1402201A (en) Assay for measuring enzyme activity in vivo
AU3162500A (en) Homogeneous fluorescence assay
AU3178200A (en) Genetic analysis
AU6458400A (en) Nucleic acid, polypeptides, assays, therapeutic methods and means
AU5245900A (en) Novel protein and dna thereof
AU2001270478A1 (en) Gene expression in biological conditions
AU2153401A (en) Gene expression in biological conditions
AU7537100A (en) Assaying in vivo t-cell response upon dna vaccination
AU2001241714A1 (en) Micro-label biological assay system
AU2464400A (en) Probe card
AU4808200A (en) Dna balls
AU5049001A (en) Dna analysis
AU6925800A (en) Autogrid analysis
AU2225401A (en) Novel protein and dna thereof
GB9905644D0 (en) Dna
AU6382000A (en) Genome analysis
AU3444300A (en) Genetic analysis
AU7300400A (en) Genetic testing
AU5494700A (en) Rna metabolism proteins
AU2001285467A1 (en) Methods for detecting mutations in the human scurfy/foxp3 gene

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 30, PAGE(S) 6231-6235 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 72957/00, 7310300, 75322/00, 75371/00, 75378/00, 75384/00, 76656/00, 76692/00, 76699/00, 76703/00, 76706/00, 77903/00, 10620/01 AND 11324/01

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase